X

Eris Lifesciences Ltd Stock Analysis

Mid Cap
Evaluated by 975 users | BSE: 540596 | NSE: ERIS |
Pharmaceuticals & Drugs

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Eris Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 065.21%68.86%46.12%38.4%45.89%51.59%30.71%23.41%22.31%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 02743935095465977508569821,074
Y-o-Y Gr. Rt.-NA43.5%29.5%7.2%9.4%25.5%14.2%14.8%9.4%
Adjusted EPS (Rs.) 02,685.134,250.654,936.576,320.329,569.0416.7320.1621.0221.58
Y-o-Y Gr. Rt.-NA58.3%16.1%28%51.4%-99.8%20.5%4.3%2.7%
Book Value per Share (Rs.) 03,470.297,687.5412,817.5419,278.5521,711.8141.2562.6483.5895.26
Adjusted Net Profit 036.958.567.986.9132230277289293
Net Op. Cash Flow (Rs. Cr.) 030.13889.690.1131200235223271
Debt to Cash Flow from Ops 00.170.070.010.01001.610.790
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Eris Lifesciences Ltd. should be analysed on a Consolidated basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NA14.5%12.7%9.4%
Adjusted EPS NA-67.9%8.9%2.7%
Book Value per Share 0-65.432.214
Share Price - - -8.8% 44.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 077.0975.9247.9839.2446.5253.0938.8228.7423.96
Operating Profit Margin (%) 021.3822.0119.4622.2628.7735.9337.6535.1734.66
Net Profit Margin (%) 013.5214.9313.3615.9322.2530.6732.5129.4727.29
Debt to Equity 00.10.0200000.440.150
Working Capital Days 006971716877101118130
Cash Conversion Cycle 00141081211-4-410
Entity Percentage Holding
Promoters 54.23%
Institutions 21.56%
Non-Institutions 24.22%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

MoneyWorks4Me analysed the past 10-year performance of Eris Lifesciences Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Eris Lifesciences Ltd is a good quality company. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company.

Data is not available for this company

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by superspecialist and specialist doctors. Eris features amongst the Top 30 companies in the Indian Branded Formulations Market.

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

  • 2007: Incorporation of the company.
  • 2007: Launched “Eris” division focused on cardiology and diabetes segment.
  • 2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
  • 2009: Launched “Adura” division focused on cardiology and diabetes segment.
  • 2011: Launched “Montana” division focused on gynecology and pediatrics segment.
  • 2012: Launched “Inspira” division focused on cardiology segment.
  • 2014: Launched “Victus” division focused on anti-diabetes segment.
  • 2014: Set up Assam Facility by the company.
  • 2015: Launched “Eris 2” division focused on pain management segment.
  • 2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
  • 2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • 2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
  • 2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
  • 2017: Eris acquires 40 trademarks from Amay Pharma
  • 2017: Eris acquires Pune based UTH Healthcare.
  • 2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
  • 2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
  • 2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback